The incidence rates of gastric cancer in these subgroups showed an increasing trend corresponding to the duration of PPI use (PPI ≥90 cDDD-days: HR, 2.498; 95% CI, 1.714 to 3.641; PPI ≥180 cDDD-days: HR, 2.252; 95% CI, 1.488 to 3.409; PPI ≥365 cDDD-days: HR, 2.187; 95% CI, 1.415 to 3.379; PPI ≥730 cDDD-days: HR, 2.249; 95% CI, 1.375 to 3.678; PPI ≥1,095 cDDD-days: HR, 2.361; 95% CI, 1.295 to 4.307; and PPI ≥1,460 cDDD-days: HR, 3.521; 95% CI, 1.426 to 8.691) ( Table 2 ).
← all excerpts
Proton Pump Inhibitors and Gastric Cancer: A Large-Scale Propensity Score-Matched Analysis.
1
—
—